Elicio Therapeutics, Inc. 8-K

What Happened

• On June 17, 2026, Elicio Therapeutics, Inc. (ELTX) filed a Form 8-K and issued a press release reporting preliminary clinical observations that the company says support evaluating its investigational cancer vaccine ELI-002 7P in combination with checkpoint inhibitors.
• The company also announced plans to conduct a Phase 1 study in first-line metastatic mutant KRAS pancreatic ductal adenocarcinoma, noting that the study is planned "subject to funding."

Key Details

• Filing date: June 17, 2026 (press release attached as Exhibit 99.1 to the 8-K).
• Program: ELI-002 7P being considered for combination with checkpoint inhibition based on preliminary clinical observations.
• Planned study: Phase 1 in first-line metastatic mutant KRAS pancreatic ductal adenocarcinoma.
• Contingency: initiation of the Phase 1 study is explicitly subject to securing funding.
• Report signed by Robert Connelly, President and CEO.

Why It Matters

• For investors, the update signals progress in Elicio’s lead clinical program (ELI-002 7P) and a strategic focus on a hard-to-treat cancer indication (KRAS mutant pancreatic cancer).
• The announcement is preliminary and the planned Phase 1 study depends on funding; there are no new financial results or definitive trial starts reported in this 8-K.